<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460499</url>
  </required_header>
  <id_info>
    <org_study_id>H-23735</org_study_id>
    <nct_id>NCT00460499</nct_id>
  </id_info>
  <brief_title>Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Heart Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine whether varying the dose of insulin and glucose in diabetic
      patients during coronary bypass surgery will improve outcomes in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous study has shown that maintaining serum glucose between 120-180mg/dl in the
      perioperative period during CABG surgery in diabetic patients improves outcomes. The purpose
      of this trial is: (1) to determine whether outcomes can be improved by altering the content
      of glucose or insulin in these solutions (2)to determine the effect of these solutions and
      glycemic control on the inflammatory response of arterial and venous conduits used during
      surgery, (3) to determine whether the beneficial effects of improved glycemic control can be
      correlated with changes in the inflammatory response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control, postoperative morbidity, inflammatory markers</measure>
    <time_frame>24 hours following surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>glycemic control</measure>
    <time_frame>24 hours following surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>free fatty acid levels</measure>
    <time_frame>24 hours following surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>B Low dose GIK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have low doses of glucose and insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C High Dose GIK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have high doses of insulin and glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive only an intravenous insulin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A IV Insulin drip</intervention_name>
    <description>These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.</description>
    <arm_group_label>A Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B Low Dose GIK</intervention_name>
    <description>These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl</description>
    <arm_group_label>B Low dose GIK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C High Dose GIK</intervention_name>
    <description>This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl</description>
    <arm_group_label>C High Dose GIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic CABG patients

        Exclusion Criteria:

          -  Renal and hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold L Lazar MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American Heart Association</investigator_affiliation>
    <investigator_full_name>Harold L. Lazar MD</investigator_full_name>
    <investigator_title>Professor of Cardiothoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

